Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 13, 2026.

The professor of neurology at the University of Alabama at Birmingham talked about findings from a CREST-2 substudy presented at ISC 2026 showing that revascularization did not improve cognitive outcomes in patients with asymptomatic carotid artery disease. [WATCH TIME: 5 minutes]

A duo of experts at ISC 2026 discussed results from a clinical trial of high-dose, home-based constraint-induced movement therapy in infants with perinatal arterial ischemic stroke. [WATCH TIME: 5 minutes]

In the phase 3 PERSEUS trial, BTK inhibitor tolebrutinib did not significantly reduce disability progression compared with placebo in patients with primary progressive multiple sclerosis.

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.

New results presented at ACTRIMS showed that in the phase 3 FENtrepid study, fenebrutinib was noninferior to ocrelizumab in reducing disability progression in primary progressive multiple sclerosis.

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.

Ava L. Liberman, MD, assistant professor of clinical neurology at Weill Cornell Medicine, shared key takeaways from stroke data presented at the 2026 International Stroke Conference.

Pediatric neurologist Charuta Joshi, MD, discussed global disparities in epilepsy for children and adolescents for International Epilepsy Day, highlighting opportunities for education, stigma reduction, and improved care access.

Here's some of what is coming soon to NeurologyLive® this week.

A real-world study showed that cladribine tablets were associated with greater treatment persistence and lower health care costs in patients with multiple sclerosis compared with other common therapies.

A new comparison study of patients with autoimmune diseases reported high rates of anxiety and depression, with notable differences in when psychiatric symptoms emerged relative to disease onset.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending February 6, 2026.

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

As part of National Women Physicians Day, a group of women clinicians discussed various topics in the care for women with movement disorders.

Epilepsy titan Page B. Pennell, MD, FAES, FAAN, FANA, outlined key hormonal, reproductive, and treatment-related factors that influence epilepsy management and outcomes for women in different life stages.

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

A duo of experts from CureDuchenne discussed how the inclusion of Duchenne muscular dystrophy on the Recommended Uniform Screening Panel can enable earlier diagnosis and inform decision-making in a rapidly evolving therapeutic landscape. [WATCH TIME: 7 minutes]

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

The associate chief medical officer at Michigan State University highlighted advances in neuromuscular disease, emerging therapeutic strategies, and the growing role of patient-reported outcomes at AANEM 2025. [WATCH TIME: 2 minutes]

The FDA raised no objections to Lexicon Pharmaceuticals’ pilavapadin for a phase 3 program, which will include 2-arm registrational studies, in patients with diabetic peripheral neuropathic pain.

If approved, lecanemab-irmb would provide an at-home subcutaneous injection option for both treatment initiation and maintenance dosing for patients with early-stage Alzheimer disease.

Here's some of what is coming soon to NeurologyLive® this week.